Amgen weakness a buying opportunity, says Cowen

Cowen would use any weakness in Amgen as buying opportunity and said the recent shortfall was due to seasonal factors and that 2014 remains on track. The firm cited company guidance, its superior profile relative to peers, potential for increased dividends, and a maturing pipeline. Shares are Outperform rated with a $131 price target.